Rejuvenation Technologies
Developer of therapeutics and research tools that target cellular aging by extending telomeres. The company focuses on transient activation of telomerase using modified mRNA, targeted delivery to specific tissues, preclinical validation, and early-stage clinical development for indications linked to short telomeres (pulmonary fibrosis, liver disease, hematologic disorders).
Industries
Nr. of Employees
small (1-50)
Rejuvenation Technologies
Mountain View, California, United States
Patents
Products
Telomerase activation program — pulmonary fibrosis (Phase I, planned)
Early-phase clinical program evaluating safety and tolerability of transient telomerase activation in patients with pulmonary fibrosis.
Telomerase activation program — chronic liver disease (Phase I, planned)
Planned Phase I program assessing safety and initial efficacy signals of telomerase activation in chronic liver disease.
Telomerase activation program — hematologic indication (Phase I, planned)
Planned Phase I program investigating transient telomerase activation to support bone marrow function and blood cell production.
TeloAid
TERT mRNA for research use to help other labs advance rejuvenation research as rapidly as possible.
TeloAT2
Investigational therapy utilizing telomerase activation via modified mRNA for patients with pulmonary fibrosis.
TeloHep
Investigational therapy utilizing telomerase activation via modified mRNA for patients with chronic liver disease.
Telomerase activation program — pulmonary fibrosis (Phase I, planned)
Early-phase clinical program evaluating safety and tolerability of transient telomerase activation in patients with pulmonary fibrosis.
Telomerase activation program — chronic liver disease (Phase I, planned)
Planned Phase I program assessing safety and initial efficacy signals of telomerase activation in chronic liver disease.
Telomerase activation program — hematologic indication (Phase I, planned)
Planned Phase I program investigating transient telomerase activation to support bone marrow function and blood cell production.
TeloAid
TERT mRNA for research use to help other labs advance rejuvenation research as rapidly as possible.
TeloAT2
Investigational therapy utilizing telomerase activation via modified mRNA for patients with pulmonary fibrosis.
TeloHep
Investigational therapy utilizing telomerase activation via modified mRNA for patients with chronic liver disease.
Services
Collaborative research partnerships with academic and industry groups to advance telomere biology and therapeutic development.
Provision of reagents for research use to external laboratories.
Coordination and enrollment support for early-stage clinical trials investigating telomere-targeting therapies.
Collaborative research partnerships with academic and industry groups to advance telomere biology and therapeutic development.
Provision of reagents for research use to external laboratories.
Coordination and enrollment support for early-stage clinical trials investigating telomere-targeting therapies.
Expertise Areas
- Telomere biology and therapeutics
- mRNA-based therapeutic development
- Lipid nanoparticle delivery
- Preclinical model development
Key Technologies
- Modified mRNA therapeutics
- Telomerase activation
- Lipid nanoparticle delivery
- Telomere length assays
News & Updates
Peer-reviewed paper reporting that transient delivery of modified mRNA encoding telomerase reverse transcriptase extends telomeres in human cells.
Company reports over 40 granted patents and over $8M in grant funding awarded since 2023.
Claimed reversal of more than five years of telomere shortening in one day in laboratory measurements.
Peer-reviewed paper reporting that transient delivery of modified mRNA encoding telomerase reverse transcriptase extends telomeres in human cells.
Company reports over 40 granted patents and over $8M in grant funding awarded since 2023.
Claimed reversal of more than five years of telomere shortening in one day in laboratory measurements.